Clinical Studies

Clinical Studies

SierraSil has been subjected to a rigorous level of testing and analysis. From these extensive assessments, experts agree that SierraSil is safe and effective in rapidly promoting joint mobility and flexibility.

1. HUMAN CLINICAL STUDY

A multi-center, double-blind, randomized, placebo-controlled study of more than 100 osteoarthritis patients was conducted at four different treatment levels (three with SierraSil, one with placebo). This study was published in the Journal of Inflammation, a peer-reviewed journal that focuses on inflammatory conditions.

RESULTS: This study provides clear evidence that SierraSil, at high and low doses, provides relief of the symptoms of osteoarthritis within two weeks of therapy.

Internationally Registered, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial #ISRCTN38432711. PUBLISHED: The Journal of Inflammation.

2. MECHANISM OF ACTION STUDY

This test was undertaken to determine how SierraSil worked on human cartilage in-vitro. The test demonstrated that SierraSil prevented the breakdown of cartilage by 68 to 73%, measured by the reduced amount of degraded cartilage debris, as glycosaminoglycans (GAG) release.

RESULTS: SierraSil appears to be an effective anti-inflammatory agent in the treatment of joint pain. These benefits are likely due to suppression of gene expression.

Miller, Mark J.S., Ahmed, S. et al. 2004. Suppression of Human Cartilage Degradation and Chondrocyte Activation by a Unique Mineral Supplement (SierraSil) and a Cat's Claw Extract, Vincaria®. Journal of the American Nutraceutical Association. Vol. 7. No. 2:32-39.

3. HUMAN PILOT STUDY

SierraSil was tested to determine if it safely provided significant improvements to pain, stiffness and inflammation in patients with previously diagnosed osteoarthritis of the knee.

RESULTS: 100% of the patients had a positive response and a reduction or elimination of their symptoms of osteoarthritis of their knees within one week of treatment. There were no reported undesirable side effects.

WOMAC (Western Ontario and McMaster Osteoarthritis Index) scoring.

4. DISSOLUTION TEST (BIOACCESSIBILITY)

A sample of SierraSil was tested to determine the bioaccessibility of minerals.

RESULTS: The bioaccessibility of aluminum, lead and iron was found to be very low.

Protocol: US Pharmacopeia 24 Method 711

5. SUB-ACUTE ORAL TOXICITY STUDY

A daily dose of SierraSil up to 1,000 mg/kg (35 times the recommended dosage) for a period of 90 days was tested.

RESULTS: SierraSil did not cause any adverse responses at the highest level taken.

Protocol: OECD No. 408